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‘There is nothing to hide’: Disclosure of PrEP use by young women in South Africa and 
Tanzania – qualitative findings from a demonstration project
Abstract
Investigating how young women disclose oral pre-exposure prophylaxis (PrEP) use is important given 
evidence that disclosure is associated with higher adherence. We report qualitative results on PrEP 
disclosure among adolescent girls and young women (AGYW) in South Africa and Tanzania who 
participated in a PrEP demonstration project (EMPOWER). In total, 81 in-depth interviews were 
conducted with 39 AGYW aged 16-24 years—25 from Johannesburg and 14 from Mwanza—at 
approximately 3, 6, and/or 9 months post-enrolment. Analysis of data was thematic and inductive. 
Most Johannesburg participants were students in the inner-city; in Mwanza, all worked in recreational 
venues, occasionally engaging in sexual transactions with customers. A continuum of approaches was 
evident. Partner disclosure was common in Johannesburg but less so in Mwanza, where many partners 
were feared as judgmental and potentially violent. In both sites, AGYW commonly disclosed to 
family to secure support, and to friends and work colleagues to advocate about PrEP and encourage 
uptake among at-risk peers. Adherence clubs appeared helpful in building AGYW’s skills and 
confidence to disclose, particularly in gender-inequitable sexual relationships. PrEP counselling for 
AGYW should focus on strengthening communication skills and help develop strategies for safe 
disclosure.
Keywords: oral pre-exposure prophylaxis; disclosure; young women; east and southern Africa
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Introduction
Nearly three decades have passed since the idea of female-controlled HIV prevention methods was 
first advanced, when it became apparent that women in sub-Saharan Africa were disproportionately 
affected by HIV (Stein 1990). Women need methods that they can initiate and control themselves—
unlike male condoms—and which could potentially be used without partner knowledge or 
participation (Becker et al. 2004; Heise 1999). From the earliest commentaries on vaginal 
microbicides and the diaphragm, to more recent studies of oral pre-exposure prophylaxis (PrEP) and 
long-acting methods such as the vaginal ring , injectables and implants, these products have held the 
promise for women, at least theoretically, of independent and covert use. 
Currently, we have a better understanding of the social and relational dynamics that shape how 
women use trial products and integrate them into their everyday lives (Stadler et al. 2014; 
Montgomery et al. 2015; Mngadi et al. 2014; MacQueen et al. 2014; Lanham et al. 2014; 
Montgomery et al. 2008). Social science research has shown that the question of independent and 
covert use is more complex than first thought. While early work on the use of female-controlled 
barrier methods suggested that women favoured covert use (MacPhail et al. 2009), recent studies have 
shown that overall, the risks of secrecy are often burdensome, with many women participating in HIV 
prevention trials in sub-Saharan Africa having pro-actively chosen to disclose product use to their 
sexual partners (Montgomery et al. 2012; Montgomery et al. 2015; Mngadi et al. 2014). Some product 
characteristics may make covert use inherently difficult to achieve (Woodsong 2004). In some 
settings there may be social expectations of partner involvement in the decision to use a product 
(Gafos et al. 2015; Woodsong 2004), especially where product efficacy is unknown. Women may 
want to pre-empt the anger of a partner discovering the product himself—an especially likely 
motivation in violent or inequitable relationships and in highly patriarchal societies (Lanham et al. 
2014; Sahin-Hodoglugil et al. 2009). 
Research in southern and east Africa has further suggested that disclosure tends to involve more 
negotiation than merely providing information. This often involves permission-seeking as well as 
cajoling, persuading, and justifying, as women skilfully weigh the risks and benefits of disclosure, and 
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strategically tailor communication with partners to maximise support for ongoing use (Gafos et al. 
2015). These observations, together with emerging evidence of the positive impact of disclosure on 
adherence, have increasingly prompted trials and demonstration projects to support product use 
disclosure (Woodsong et al. 2013).
To date, most research on disclosure has involved topical microbicides (Succop et al. 2014; Gafos et 
al. 2015), which have shown limited efficacy in trials (Baeten et al. 2013). Oral PrEP marks a 
departure from these earlier methods on several levels. Firstly, it is known to be effective when used 
consistently during peri ds of high risk (Marrazzo et al. 2015), and it is the first woman-initiated new 
product for HIV prevention to be licensed. Secondly, PrEP signals the shift to systemic rather than 
topical methods of HIV prevention, and thirdly, its physical form—a daily pill that can be discretely 
swallowed—may have implications for disclosure that are quite distinct from vaginal products. These 
novel dimensions to oral PrEP warrant closer investigation, especially given evidence showing 
associations between disclosure and higher adherence (Montgomery et al. 2015; Ware et al. 2012; 
Corneli et al. 2015). Understanding how and why women choose disclosure over covert product use 
could help inform interventions to support disclosure, particularly in settings where young women 
face stigma or gender-based violence (GBV), both of which remain extremely common in southern 
and east Africa (Decker et al. 2015). 
In this article we report on results from a qualitative study among adolescent girls and young women 
(AGYW) in South Africa and Tanzania who participated in a demonstration project that included 
daily oral PrEP. Much of the literature on novel HIV prevention methods for women has focused on 
negotiation of product use with male partners. We describe how participants approached product use 
disclosure to sexual partners, but also to family members and friends. Broadening the scope of 
enquiry to include others beyond sexual partnerships recognises that social networks may be critically 
important for young women as they attempt consistent daily pill use. 
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Methods
Between February 2017 and February 2018, we conducted serial in-depth interviews (IDIs) with a 
sub-sample of study participants in the EMPOWER (Enhancing Methods of Prevention and Options 
for Women Exposed to Risk) demonstration project, which sought to assess the acceptability and 
feasibility of an HIV prevention package, including oral PrEP. Women aged 16-24 years were 
recruited in inner-city Johannesburg, South Africa, and Mwanza city, Tanzania. At the time, PrEP was 
licensed in South Africa, with government focussing its introduction to prioritised populations. In 
Tanzania, PrEP was not yet licensed. In both countries, PrEP outside of this study setting was largely 
unheard of as an HIV prevention method.
Women who were HIV negative, not pregnant and interested in taking daily PrEP were enrolled, 
offered Truvada, and followed up for 6-15 months. At quarterly clinic visits, women received HIV 
testing and counselling, screening for GBV, and sexual and reproductive health services. Referrals 
were provided as needed. All women received PrEP adherence counselling with follow-up messaging 
through SMS. Additionally, half the participants were randomly chosen to participate in monthly 
adherence support clubs, which included a four-session empowerment curriculum. These clubs were 
designed to offer additional PrEP adherence support, and build resilience to stigma, GBV, and 
relationship conflict. Possible disclosure scenarios were discussed in club sessions and further 
disclosure support was offered during individual counselling at study visits. 
The study was approved by the Human Research Ethics Committee of the University of the 
Witwatersrand, the London School of Hygiene and Tropical Medicine Ethics Committee, and the 
Tanzanian National Health Research Ethics Committee of the National Institute for Medical Research.
Qualitative sub-study: sampling and data collection
Participants enrolled for at least three months, who had accepted PrEP, were purposively sampled to 
capture a spread of PrEP experiences and be representative of the study population. Efforts were made 
to sample participants who had: initially declined PrEP at enrolment, disclosed experience of GBV at 
screening, or been placed on product hold for medical reasons, including pregnancy. Participants were 
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approached by telephone or in person by a member of the qualitative research team and invited to 
participate in the IDIs. The target sample size was 25 participants in each site.
Serial IDIs aimed to capture how participants’ overall experience of PrEP-taking changed over time. 
In Johannesburg, participants were interviewed 1) after three months, about motivations for PrEP 
uptake and initial challenges experienced with product use; 2) after six months, focusing on barriers to 
adherence; 3) around nine to twelve months after enrollment about participants’ experiences of the 
study interventions. In Mwanza, interviews were held after three and six months only.
Detailed IDI guides were developed by the qualitative research team, then field tested and refined 
with members of the Johannesburg Youth Community Advisory Board. The guides were reviewed 
after the first interviews and adapted to include new questions and refine probes. In all interviews, 
PrEP disclosure was discussed using probes that encouraged participants to talk about their decision 
to disclose or not, whether disclosure had been intentional, and the reaction to disclosure. Three 
trained interviewers conducted the interviews in private at the clinic in the participant’s preferred 
language (English, isiZulu, seSotho or Swahili). Interviews lasted between 20-60 minutes, were 
audio-recorded, transcribed verbatim, and translated into English, where necessary. Quality and 
accuracy of transcriptions were checked against audio recordings by the interviewers, before being 
uploaded to a secure database. Interviewers received refresher training as necessary.
Data analysis
Analysis followed a thematic, inductive approach (Glaser and Strauss 1967), with key themes 
identified directly from interview data. A provisional codebook was developed following open coding 
of a small selection of transcripts by members of the qualitative team. Two coders then independently 
coded the same transcript and inter-coder reliability (ICR) was assessed using QSR NVivo V.11. ICR 
was set at 0.75 and re-coding of a common transcript continued until this level of agreement was 
achieved. Thereafter, the codebook was finalised and remaining interview data inductively coded by 
four coders (FS, NK, LR, EM). Coding was reviewed regularly by FS, and discrepancies discussed 
with the relevant coder until agreement was reached on the best applicable code. Reports were 
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generated for specific nodes and summary matrices developed to examine intersecting themes. Two 
coding and analysis workshops were held to discuss interpretation of the data. 
A matrix of summarised information on PrEP disclosure patterns across all qualitative participants 
and interview rounds was developed. ‘Full disclosure’ was defined as telling another person that one 
is taking oral PrEP to protect oneself from HIV, while ‘partial disclosure’ was defined as revealing 
only some of this information.
Study settings
In Johannesburg, EMPOWER study participants were recruited from the inner-city neighbourhood of 
Hillbrow and surrounds. This is a densely populated neighbourhood characterised by high-rise 
apartment blocks, which are overcrowded and often unsafe, with frequently interrupted power and 
water supplies. With a number of schools and tertiary education colleges nearby, many young people 
reside in or travel into the area daily.  
Mwanza, Tanzania’s second largest city, is located on the shores of Lake Victoria. Around 10% of the 
city’s population (approximately 500,000) are estimated to have migrated from rural areas. 
Opportunities for poorly educated migrant women are often limited to setting up small businesses or 
engaging in petty retailing (Ellis et al. 2007). More formal employment may be found in bars, 
guesthouses, and clubs across the city, where many of the women in this study were recruited. 
Results
In Johannesburg, 25 participants were recruited, of whom nine women completed three interviews, 12 
completed two, and four completed one interview. In Mwanza, 12 participants were interviewed 
twice, and two interviewed once.
Key characteristics of study sample
Overall, the qualitative sample reflects the demographics of the overall study and captures key 
differences by study site (Table 1). Median age across both sites was 20.5 years old (IQR 19-22). 
Around half the Johannesburg sample were tertiary-level students, while a third had completed high 
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school and were seeking employment. All were living with parents, other relatives or in student 
residences. By contrast, most of the Mwanza participants had completed primary school only. All 
worked in recreational venues or in food and alcohol outlets, where occasional sexual transactions 
with customers are the norm. Most were living alone or with family members.
Prevalence of GBV was high, with roughly half (both sites) reporting ever experiencing physical, 
sexual or emotional violence. PrEP uptake was also high: 23 of the 25 participants in Johannesburg 
and all 14 participants in Mwanza accepted PrEP at enrolment. 
[Table 1 about here]
Disclosure to sexual partners
Sixty-four percent (16/25) of Johannesburg participants had disclosed PrEP use—fully or partially— 
to partners by the first interview, compared to two of the 14 Mwanza participants. This pattern did not 
significantly change during the study. At both sites, a range of approaches towards partner disclosure 
of PrEP was evident, from reluctance and prevarication to pragmatism and bold decisiveness. This 
continuum from non-disclosure to full disclosure is similar to that used in studies of other candidate 
HIV prevention methods (MacPhail et al. 2009; Lanham et al. 2014; Sahin-Hodoglugil et al. 2009). In 
disclosing to partners, participants tended to explain PrEP use as a procedure required for study 
participation, and thereafter as ‘a pill that prevents HIV’. In some cases, extra care was taken to 
distinguish PrEP from ARVs as treatment.
Full disclosure was mostly evident at the Johannesburg site (Jhb), where a number of women framed 
the decision to start PrEP as a choice already made—a fait accompli—with no need for partner input 
and apparently little regard for what his response might be. Portia’s1 view on this was unambivalent:
If I want to take [PrEP], I can take it whether he likes it or not (laughs) because it’s me, it’s my 
body. (21 years, Jhb; IDI-113B)
Buhle told her partner within a week of starting PrEP:
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I didn’t fear anything, actually. I didn’t care what people said, after all, it’s my life. His 
response was ‘OK, it’s fine’. (18 years, Jhb; IDI-153F)
In many cases, this confident approach was driven by a desire for honesty and openness in the 
relationship. Most Johannesburg participants reported that their partners were supportive of their PrEP 
use, with some apparently asking if they, too, could join the study and access PrEP, while others 
helped by reminding women to adhere to their daily regimen. Some partner responses were reported 
to be less positive, especially where partners were sensitive to doubts about their fidelity and HIV 
serostatus. Disclosure had the potential to bring latent mistrust in the relationship into sharp relief, 
potentially triggering conflict and counteraccusations. 
Women at both sites navigated these situations with enormous skill, developing tactics to manage 
their partner’s response and retain control of the narrative when met with resistance or anger. One 
such tactic involved openly asserting one’s right to be protected from infection, mobilising arguments 
about self-preservation. Portia, for example, acknowledged her partner’s other relationships, but did 
not back down on asserting her right not to be infected.
He was like, ‘so you don’t trust me, you think that I’m not faithful?’ and all that. And then I told 
him, like, that because he once cheated on me…I told him that ‘I trust you but I don’t want 
mistakes. What if you get tempted and cheat and cheat with a wrong person and you come and 
infect me?’ And then that’s how he understood. (21 years, Jhb; IDI-113B)
Similarly, Olivia—one of only two women in Mwanza (Mwz) to disclose PrEP use to a sexual 
partner—claimed her husband’s untrustworthy behaviour posed a threat to her wellbeing. 
He had two other girls out there…I continued using the pills and I made sure that he knew 
about it and I told him that he wasn’t settled and so it’s better if I protected myself. He asked 
me where I got the pills, I explained, then he allowed me. (24 years, Mwz; IDI-ET0017D)
Part of this strategy involved justifying PrEP use as an act of self-care or as a step they were 
compelled to take in order to ‘be safe’. When Lerato’s partner questioned her decision to take PrEP, 
she responded:
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…it’s just PrEP but I’m just taking care of myself, at the end of the day I have to think about 
myself and not another person. (23 years, Jhb; IDI-235Z)
Other strategies involved suggesting how her PrEP use could benefit him. Theresa used this approach 
to win her partner’s support: 
Eh, at first he was like, ‘why are you taking PrEP?’ [I said] ‘I want to prevent myself.’ ‘From 
what? [he asked] – am I HIV positive?’ I said ‘no, I don’t think so. At the end of the day I’m 
protecting you from your side’, So when I told him ‘I’m protecting you’, ja, he started being 
happy and said ‘fine, at least I’m not gonna be infected’. (18 years, Jhb; IDI-440G)
Another approach—and one that falls closer to the ‘non-disclosure’ than the ‘full disclosure’ side of 
the continuum—involved strategically guiding a partner’s attention to something other than PrEP. 
Katleho, for example, told her boyfriend she was taking PrEP but said she had been motivated by the 
benefits of study participation, rather than access to PrEP itself.
…he was a bit angry, ‘how come you don’t trust me?’ Then I said I wanted to be in the study…I 
want to be checked [for HIV and other health conditions] after every 3 months. (20 years, Jhb; 
IDI-206G)
Nsekelwa managed to secure her partner’s permission to use PrEP by diverting attention away from a 
potentially uncomfortable discussion of sex and trust.
On the first day when I told him he asked why I didn’t trust [him], to begin using the 
medicines... And I also told him ‘Aaaah! [No] it’s not that HIV can be caught in sex only, it 
could happen maybe by sharing sharp objects then you catch HIV. After that explanation, he 
allowed me because I explained and he understood and agreed. (22 years, Mwz; IDI-ET0083I)
A fourth strategy involved partial disclosure through the telling of a ‘half-truth’ or simply not 
correcting a partner’s misperception. For example, a handful of women in Johannesburg allowed their 
partners to assume that the pill they were taking was for contraceptive purposes. In South Africa, 
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contraception is often colloquially referred to as ‘prevention’, making it possible to exploit this 
slippage of terms to conceal PrEP use.
In most cases, it was the fear of conflict, stigma and judgement that necessitated evasive approaches 
to disclosure; these were prominent themes in the interviews, regardless of setting. Rosemary 
remarked that if her partner found out she was taking PrEP, ‘he may even beat me up’ (20 years, 
Mwz; IDI-ET0079Q). Fear of partner response also appeared as a strong motive for non-disclosure 
among the Johannesburg participants; about a third had not disclosed to their partners by the second 
(six-month) interview. They anticipated a range of angry responses from partners; one woman said he 
would ‘throw the pills away’; another said, ‘World War III will start’. Cecilia insisted she would 
never disclose to her partner and maintained that by doing so, ‘I’m avoiding many problems…it would 
be a long conversation…I don’t even touch the subject’ (18 years, Jhb; IDI-346Z). Unsurprisingly, 
non-disclosure of PrEP use was more common in relationships with low levels of trust, and where 
women feared violence. Dikeledi described her partner of six years as jealous and controlling and said 
he had tried to strangle her in the past. She was adamant that disclosure was out of the question and 
that by staying HIV negative through taking PrEP, she could avoid conflict and recriminations later.
I don’t tell him that I am taking PrEP because if he is doing things outside [having other 
partners] …I don’t expect him to say I am the one who made him sick because I will be safe 
and he will be the one who is sick at that time. (22 years, Jhb; IDI-084Q)
Importantly, not all decisions to use PrEP secretly were based on fear of partner response. In 
Johannesburg, sharing such sensitive information would be considered inappropriate in a relatively 
new relationship. Maria had not disclosed to her partner of two months: ‘if I see that things now are 
getting too serious….Then I will tell him the truth’ (20 years, Jhb; IDI-418D).  Zukiswa (Jhb), having 
recently reunited with her partner after a break-up, felt relations between them were too fragile for her 
to disclose, although she planned to do so eventually to pre-empt his suspicion about her multiple 
clinic trips. So, partner type – new or casual versus stable, long-term partner – in part determined 
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whether women considered covert use of PrEP to be necessary, an assessment that could shift as the 
relationship changed.
These findings on the challenges of communicating about PrEP use within relationships raise the 
question of whether the study interventions had any impact on women’s ability or willingness to 
disclose to partners. In these interviews, most commentary focused on the experience of participation 
in the clubs. In Johannesburg, we explored whether partner disclosure patterns were shaped by study 
arm allocation. Here, almost all (11/13) of the qualitative participants assigned to the club arm had 
disclosed PrEP use to their partner, compared to only half (6/12) of the participants receiving standard 
adherence support. Club participants reported boosted confidence levels and strengthened 
communication skills, often using practical role-play exercises, which in turn may have facilitated 
disclosure to an intimidating partner. Additional support for disclosure may have come from the 
strong emphasis in club sessions on open communication and shared responsibility for decision-
making within sexual partnerships:
In terms of relationships, eh, I have learned that communication is key, you see when you 
communicate, you do not do something just because another person wants you to do it, you 
both need to take decisions as a couple, you need to be responsible for those decisions. 
(Nomzamo, 21 years, Jhb)
Disclosure to family members, friends, and work colleagues
Compared to partner disclosure, with family members there were clear shifts in the patterns of 
disclosure across time, i.e. between the first and the final interviews. Full disclosure to trusted female 
family members (mothers, aunts and sisters) featured prominently in the first interview; participants 
described being “close” to these family members and actively seeking to share their decision about 
PrEP with them. Parents and other family members believed to be potentially disapproving or 
judgemental were usually not told until much later in the study. Xoliswa initially only told her mother 
and sisters about her PrEP use, and delayed telling others in her family as she feared their response.
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My father, my grandmother, okay, ja, all of them because I was scared that maybe they will 
think I am doing something like…maybe I am sleeping around or that’s why I am doing that. 
(21 years, Jhb; IDI-200I)
By the 6-month interview, Xoliswa reported having disclosed to her grandmother. Still nervous of 
how her father might respond, Xoliswa had asked her grandmother to inform her father about her 
using PrEP.
In Mwanza, the strongest motivation for disclosing PrEP use to family members was overwhelmingly 
women’s need to explain their frequent clinic visits and the presence of pills in the home. In keeping 
with a social norm of children displaying respect for parents and older relatives, women believed they 
needed “permission” for PrEP uptake, particularly if living with their parents. Rosemary, who works 
as an attendant at a hotel, told her father, mother and sister, and explained:
How do I go out from home without permission and I must explain where I am going?…I also 
chose consciously not to hide because I live with them. (20 years, Mwz; IDI-ET0079Q)
Agnes also told her mother, because: 
When I thought of what she would think if she was to find the medicine in the house and she 
asks me about them, so I thought it was wise to tell her. (21 years, Mwz; IDI-ET0082A)
At both sites, however, some women had hidden their PrEP use from parents. Nomzamo had used 
PrEP in secret for a month. But adherence was difficult under such circumstances. She recalls, ‘I had 
to hide the pills...ya, you are not free in the house’ (21 years, Jhb; IDI-112Y). 
Like Nomzamo, other participants initially found it difficult to be open about PrEP with family 
members, but at the same time struggled to conceal PrEP in the home. Phindile started to take PrEP 
surreptitiously after initially showing her mother the study pamphlet:
I told her that they want me to take PrEP and she just said no, she said ‘if you do it, then just 
know that you would be doing it against my will.’ You know when a parent says that, yoh, yoh, 
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it’s heart-breaking, she makes you feel bad”. [But] I just had no say. She just said that that was 
it. (19 years, Jhb; IDI-26U)
Phindile would watch her mother’s movements and ‘look if there is anybody watching, and…sneak 
into the room [to take PrEP]. It’s a bit difficult…exhausting’. In Johannesburg, participants who 
attempted covert PrEP use at home did so largely because they wanted to hide from their parents that 
they were sexually active. Refiloe, a 19-year-old student, hid her PrEP pills among her clothes in her 
wardrobe to conceal them from her mother. She reflected on the consequences of being found out: 
I don’t want to see their reaction, first of all, they would ask, they will be shocked that I am 
even sexually active…That would lead to so many questions. (Jhb; IDI-095X)
In Mwanza, however, having sexual partners was not something participants needed to conceal from 
parents, who often knew about the kind of work they were doing in local bars, taverns and other food 
and entertainment venues. Both participants and their families seemed acutely aware of the 
heightened risk of HIV acquisition they faced in the workplace and the lack of alternative 
employment options for women in this setting. Being open about their PrEP use to family members 
thus became a way for women to reassure them that th y were safe. Rodia used this approach with her 
mother:
I told her the environment where we work is filled with risks...You might be caught up in a 
relationship with an infected person, so the pills help you prevent the risks of infections. (24 
years, Mwz; IDI-ET0089N)
For the same reason, many participants were motivated to disclose PrEP use to female peers and 
colleagues at work, in the hope that they, too, would join the study and protect themselves from 
infection. Indeed, this is often how PrEP was pitched to this group. Wakuru advised her co-workers at 
the bar that PrEP offered an alternative to male condoms. 
For example, you have a lover and maybe he doesn’t want to use condoms...Since there is PrEP 
which helps you; even if he has his own other doings, when you rightly focus on taking the pill 
everyday...even if they meet with their lovers and they are infected, but due to the immunity that 
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is already built up with PrEP, it’ll be a safe way to avoid infections. (20 years, Mwz; IDI-
ET0018E)
Participants in Johannesburg were equally aware of the elevated HIV risks faced by young women in 
their environment, citing their peers’ (and partners’) reluctance to be HIV tested and the high rates of 
sexual assault as motivations for PrEP use. Telling friends about PrEP therefore often involved 
directly pointing out their risk and encouraging them to take PrEP. Tumi, who joined the study 
because she once had a friend who was HIV positive and didn’t want to see herself ‘in the same 
situation’, told all her friends she was taking PrEP and urged them to do so as well.  Being open about 
this strengthened Tumi’s sense of purpose in being among the first among her peers to adopt PrEP: ‘I 
feel proud about myself. So that they know that we are bringing change’ (21 years, Jhb; IDI-085K). 
Refiloe similarly turned disclosure to friends into an opportunity to educate:
I know we are all sexually active so I told them so that they could think about joining…Ja, and 
they always complaining about HIV, pregnancies and all that. So I was like, ‘let me just give 
you one option to think about so that you could decrease your worries’. (19 years, Jhb; IDI-
095X)
Indeed, some of these participants went beyond mere disclosure to embrace pro-active promotion of 
PrEP among peers and even among strangers in the broader community. Alice, for example, felt 
strongly about this advocacy role.
There is nothing to hide...It’s PrEP, it’s for everyone, so I shouldn’t wait for people to ask me 
‘hey what are you doing?’ No, it’s a feeling like I should let people know about this. It should 
be all over the world, people should be asking about it…’cos it’s not for myself, it’s for 
everyone else…I feel very open, like I should be having a mic[rophone] and telling everyone 
about PrEP (laughs). (22 years, Jhb; IDI-446R)
Disclosure to a friend was extremely common (23/25 in Jhb, 10/14 in Mwz), and tended to happen at 
an early stage of taking PrEP. By the final interview, several participants had also disclosed to a much 
wider circle, such as church members, work colleagues, and acquaintances.
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There were reportedly mixed responses from family members and friends. The novelty of PrEP and 
its relatively unknown status, especially in Tanzania, meant that some family members simply did not 
believe in its existence. Rosemary maintained that her mother and brother insisted that she was living 
with HIV and taking antiretrovirals, even challenging her to bring ‘documentation’ back from the 
clinic to prove her HIV-negative status. Responses of outright disbelief were reported as less common 
in Johannesburg but there was scepticism that a pill alone could prevent HIV infection, and general 
mistrust in clinical research. While in most cases, friends expressed interest in PrEP and in joining the 
study, some had apparently teased the participants about taking antiretrovirals or about being tested as 
‘guinea pigs’ in research.
Negative responses from family and friends appeared to be the exception rather than the rule. The 
omnipresence of HIV in the broader environment meant that family members more often openly 
welcomed participants’ decision to use PrEP. In both sites, overwhelmingly, parents reportedly 
expressed relief that their daughters were actively doing something to protect themselves from HIV. 
Xoliswa’s mother responded ‘aah, at least you are safe’ (21 years, Jhb; IDI-200I), while Amina’s 
grandmother was happy the clinic was providing PrEP to young women because ‘many girls are 
ruined’ (22 years, Mwz; IDI-ET0013Q). 
In Johannesburg, the response of parents and other family members was often shaped by their direct, 
personal experience of HIV. Zama’s mother is living with HIV; she apparently understood 
immediately when her daughter told her about PrEP and saw it as ‘a good thing’ (24 years, Jhb; IDI-
192H). When asked by her mother why she was taking PrEP, Dikeledi recalled that her response was:
Remember one of your cousins passed on because of HIV and got it from the boyfriend? So I 
don’t want history to repeat itself, my child is still young. (22 years, Jhb; IDI-084Q)
Karabo told her parents about PrEP because ‘they know this container...I don’t want them to think 
otherwise’ (22 years, Jhb; IDI-08J). Her mother was not surprised and saw Karabo’s decision as 
positive, setting her apart from the actions of a cousin, ‘the one they trusted so much’, who had 
contracted HIV. A number of the Johannesburg participants mentioned that their decision to initiate 
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PrEP was praised by their mothers, who appeared to interpret this as a sign of maturity. Naledi 
described her mother’s response: 
She said it’s best to protect yourself…‘I’m very proud you are doing something, you have a 
child now, now you know what’s wrong, what’s right’. (22 years, Jhb; IDI-263J)
Similarly, Theresa’s mother, a nurse, had approved her daughter’s decision to take PrEP saying, ‘now 
you are actually grown up, you decided to go there by yourself’ (18 years, Jhb; IDI-440G). When 
Buhle told her sisters,
‘They were proud of me actually, ‘cos they didn’t know about the pill, ja and I was seen as this 
responsible young lady. I was very happy. (18 years, Jhb; IDI-153F)
Discussion
In assessing patterns of and motivations for PrEP disclosure among AGYW in South Africa and 
Tanzania, we found important distinctions that likely derive from socio-demographic differences 
between the two study sites. In Johannesburg, there was evidence of autonomous decision-making 
about HIV prevention—possibly a function of higher education levels—and a strong trend towards 
disclosing PrEP use to sexual partners. Disclosure to a broader network of family and friends was 
partly influenced by acute awareness of HIV risk and sexual violence at community level, and was 
often received with empathy and support, particularly by those directly affected by HIV. By contrast, 
the dominant pattern in Mwanza was non-disclosure to partners, who considered highly likely to 
judge and condemn women taking PrEP. This may reflect the participants’ relative lack of power vis-
à-vis male partners, as well as local stigmatising discourses about sex, gender and disease. We saw a 
strong trend of women disclosing PrEP use to friends and work colleagues, mainly as a way to 
encourage PrEP uptake among this broader, at-risk group. As in Johannesburg, disclosure to parents 
was common in Mwanza, with women appearing to seek parental permission as well as offering 
reassurance that—as young women working in a high-risk environment—PrEP made them ‘safe’. In 
both sites, there seemed to be a pattern of first disclosing to supportive female family members, and 
later to older and male family members, or those initially feared as potentially judgmental of young 
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women’s sexuality. More ‘public’ disclosure became easier for women in the later months of the 
study.
This was a relatively young cohort of women, with many unmarried and living with family, which 
likely shaped their disclosure decisions. For younger women, their parents seemed to be more obvious 
‘gate keepers’ to PrEP uptake than their partners. This may point to shifts in inter-generational 
relations between adolescents and adult caregivers that facilitate more open discussions about 
sensitive issues like sexual activity and HIV than was possible in the past. It is significant, perhaps, 
that in Johannesburg some parents approved of PrEP use and regarded it as a positive sign of maturity 
and responsibility—a possible framing that could help to counteract PrEP stigma against young 
women. In Mwanza, family dynamics appear to be shifting together with recent rural to urban 
migration, with evidence that sexual education now tends to be administered by mothers in urban 
areas, whereas, in the past, it was largely administered by grandmothers and female elders (Lees 
2013). 
Participants’ experiences of attempted covert use of PrEP illustrate the social obligations and 
gendered norms that young women—especially in the Johannesburg site—are under pressure to 
respect, namely, the expectation that they delay sexual debut. These experiences also bring to light the 
practical challenges of daily pill-taking under the watchful eyes of others who share the same living 
space. Since residences in these settings are often cramped and overcrowded (Scorgie et al. 2018), this 
may have restricted privacy for those who wished to hide their PrEP, ultimately forcing disclosure to 
household members. Arguably, PrEP’s ‘visibility’ in this context is increased by its resemblance to 
antiretrovirals, its daily regimen, and need for pill storage, suggesting that the physical characteristics 
of the product itself may also have shaped disclosure within households. Other, more discreet, forms 
of systemic PrEP currently under development may be less visible by comparison, thereby removing 
this challenge altogether.
The high proportion of participants who told at least one friend or colleague about their PrEP use 
points to the ‘social and connected lives’ (Haberer et al. 2019) of AGYW, where decisions and 
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experiences are frequently shared with peers. Increasingly, peer relations in these settings are shaped 
by widespread use of social media, with young people increasingly attuned to the crafting of new, 
gender equitable identities—even if social norms and institutions lag behind. The importance of these 
early PrEP adopters sharing their experiences with peers who are similarly at high risk of HIV cannot 
be overstated. Through participation in projects such as EMPOWER, they have the potential to 
influence future uptake among peers and male partners, and to shape attitudes at community level, 
potentially normalising women’s autonomous use of HIV prevention methods. Given the prevalence 
of PrEP stigma in both study sites, this aspect of disclosure potentially gives it a potency beyond 
impacting on the individual PrEP user alone.
Across the continuum of approaches used when disclosing to partners, it was evident that women 
considered the nature of the relationship, anticipated their partner’s response, and skilfully controlled 
what information to convey, even resorting to deceit if needed. For most participants, low levels of 
trust and partners’ controlling behaviours determined how much communication about PrEP use was 
possible, if at all. This was particularly true for Tanzanian participants, where sexual relationships are 
marked by stark gender inequalities and women’s economic dependence on male partners. 
Consequently, there was more covert use with sexual partners than in South Africa, where gender 
norms are more in flux. In Johannesburg, the framing of PrEP use as an act of legitimate self-care to 
which women are entitled, speaks to the prominence of discourses about gender equality and women’s 
empowerment in this fast-paced urban environment, where independence and agency are highly 
valued among young people. In this context, it makes sense that PrEP use should be claimed by them 
as an individual right. More broadly, the trend of a new generation of young women becoming more 
aware and assertive about their sexual and reproductive health rights is partly attributable to the long 
history of research on HIV prevention products for women in the region. 
Along with PrEP advocacy in PrEP naïve communities, adherence clubs appeared to be helpful in 
building positive social norms around women’s use of this new HIV prevention technology. Although 
not examined here in detail, there were signs that through the use of practical scenarios to rehearse 
safe disclosure with partners, clubs strengthened confidence and communication skills, thereby 
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supporting women who chose to disclose. Indeed, PrEP adherence clubs in other studies have been 
effective in offering peer support for adolescents taking PrEP, including support to disclose to others 
and overcome stigma (Celum et al. 2019). Initiatives that include participants’ support networks and 
those that help participants to convey simple, factual information about PrEP are also potentially 
important (Toledo et al. 2015).
There were limitations to the study. Interviewing participants at the clinic may have led them to avoid 
saying anything negative about the study or about PrEP use. The small study samples make it difficult 
to be definitive about trends such as the apparent association between club attendance and disclosure 
to partners. We also did not interview the partners, family members and friends of study participants, 
and our conclusions about their responses to PrEP disclosure should be read with caution.
Understanding young women’s decision-making around PrEP disclosure may help inform PrEP 
delivery services and scale-up, as well as efforts to ‘normalise’ PrEP use among young women more 
generally. Where possible, PrEP counselling should enhance communication skills and develop 
strategies for safe disclosure. In doing so, the risk of partner violence must be recognised in 
relationships with controlling behaviours, insecure partners or a history of violence. Women require 
support in such situations and careful discussion of their fears. Future messaging around PrEP may 
also need to address the assumption that a male partner of a woman taking PrEP is directly protected 
from acquiring HIV. Not only is this perception potentially harmful, it could unfairly place the onus 
for men’s HIV prevention on women. 
Finally, our study findings support recent recommendations that PrEP be marketed to AGYW as an 
empowering ‘lifestyle choice’ rather than more narrowly as a biomedical HIV prevention tool 
(Haberer et al. 2019). Where young women can see PrEP initiation as a self-affirming, positive step, 
there is potential for the claiming of a new, socially empowered identity. Supporting women to talk 
openly about their PrEP use and spreading the word about its efficacy lays a foundation for scaling up 
and introducing future technologies—like long-acting injectables or implants—moving us closer to a 
time when young women’s use of HIV prevention is regarded as unexceptional.
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Table 1. Baseline demographic characteristics of participants in the qualitative sub-samples and 


































































































Number of sexual partners
None
One









































Screened positive for GBV 13 (52) 7 (50) 121 (32) 20 (38) 141 (33)
PrEP uptake
Accepted PrEP at enrolment
Accepted PrEP by M12
















*Includes women living in student residences
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